secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001437749-25-000932
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex provides clinical trial updates for Acclaim-1, Acclaim-3, and diabetes gene therapy program
--------------------------------------------------------------------------------

- Acclaim-1 Phase 2a expansion enrolling; interim analysis after 19 patients expected H2 2025.
- Acclaim-3 Phase 2 expansion opened; enrollment of first 25 patients for interim analysis expected H2 2025.
- Diabetes gene therapy program licensed from Univ. of Pittsburgh; seeking FDA guidance for IND-enabling studies in H2 2025.
- Acclaim-1 has FDA Fast Track; Acclaim-3 has Fast Track and Orphan Drug designations.
- Initiated research on non-viral lipid nanoparticle delivery system for diabetes program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925000932/0001437749-25-000932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925000932/gnpx20250105_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-000932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer